A patient with treatment-resistant depression and psychogenic non-epileptic seizures (functional seizures) experienced resolution of both conditions after receiving esketamine, a drug approved for treatment-resistant depression and major depressive disorder with suicidal thoughts. The report discusses the potential therapeutic effects of esketamine on functional seizures beyond its antidepressant properties.
Psychedelic medications and cannabinoids are emerging as effective treatments for major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder, though they produce mild adverse effects. This conclusion comes from a review of 16 studies comparing new pharmaceutical interventions against mental illnesses.